This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020
by Zacks Equity Research
Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.
Blueprint Medicines, Roche to Develop Pralsetinib for Cancer
by Zacks Equity Research
Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.
Axsome's NDA for Depressive Disorder Drug on Track in Q420
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
by Zacks Equity Research
Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.
Celsion Down on DMC Recommendation to Stop Liver Cancer Study
by Zacks Equity Research
Celsion (CLSN) plummets on DMC recommendation to stop its phase III study assessing the efficacy of ThermoDox for HCC.
AbbVie (ABBV) Gets FDA Nod for Another Botox Label Expansion
by Zacks Equity Research
AbbVie (ABBV) wins the FDA nod for an expanded use of Botox to treat spasticity in pediatric patients aged two years and above including those with lower limb spasticity caused by cerebral palsy.
Abeona Restarts Enrollment in Connective Tissue Disorder Study
by Zacks Equity Research
Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.
CorMedix (CRMD) Jumps: Stock Rises 7.5%
by Zacks Equity Research
CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Unum Therapeutics (UMRX) Catches Eye: Stock Jumps 8.6%
by Zacks Equity Research
Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
BioMarin's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in BioMarin Pharmaceutical.
Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF
by Sweta Killa
In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.
REGN vs. BMRN: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. BMRN: Which Stock Is the Better Value Option?
REGN vs. BMRN: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. BMRN: Which Stock Is the Better Value Option?
Why Is BioMarin (BMRN) Up 14.8% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Beats on Q1 Earnings, Lowers Sales View
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the first quarter. It lowers its total revenue outlook for the year due to the potential impact of coronavirus outbreak.
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 90.91% and 6.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Down 8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus
by Zacks Equity Research
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.
Stock Market News for Feb 27, 2020
by Zacks Equity Research
U.S. equities disappointed on Wednesday, as most of the major benchmarks ended mostly lower.
BioMarin Pharmaceutical (BMRN) Q4 Earnings Top Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 19.05% and -1.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.
BioMarin (BMRN) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
BioMarin (BMRN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU
by Zacks Equity Research
BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%
by Zacks Equity Research
BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
BioMarin (BMRN) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
BioMarin (BMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.